⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435148 | 0.83 | ADORA3 (0.31) | — | |
| SCHEMBL14030991 | 0.77 | HPGD (0.36) | — | |
| SCHEMBL27638169 | 0.75 | — | — | |
| SCHEMBL691440 | 0.74 | ALDH1A1 (0.46) | — | |
| SCHEMBL4062568 | 0.74 | RPS6KA5 (0.47) | — | |
| SCHEMBL4596427 | 0.72 | RORC (0.32) | — | |
| SCHEMBL14031147 | 0.70 | — | — | |
| SCHEMBL5608053 | 0.64 | GRM2 (0.30) | — | |
| SCHEMBL14031604 | 0.64 | TLR7 (0.40) | — | |
| SCHEMBL4243865 | 0.63 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2286232-B1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2286232-B1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2012-02-29 | — | — | EP | disclosed |
| CN-102027371-A | Methods for the identification of PARP interacting molecules and for purification of PARP proteins | CELLZOME AG | 2011-04-20 | — | — | CN | disclosed |
| US-20110070595-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG | 2011-03-24 | — | — | US | disclosed |
| US-20110070595-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG | 2011-03-24 | — | — | US | disclosed |
| EP-2286232-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2011-02-23 | — | — | EP | disclosed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| WO-2007058850-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058852-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| CN-1859912-A | Inhibitors of Akt activity | SMITHKLINE BEECHAM CORP (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1682123-A1 | CANCER TREATMENT METHOD | SmithKline Beecham (Cork) Limited (IE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005046678-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |